Stockreport

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla, Inc.  (BCAB) 
PDF SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Ac [Read more]